DOCSLIB.ORG

AMR2018 Cover Final Copy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AMR2018 Cover Final Copy AMR CONTROL 2018 OVERCOMING GLOBAL ANTIMICROBIAL RESISTANCE EDITORS-IN-CHIEF: DR JEAN CARLET, PRESIDENT, WORLD ALLIANCE AGAINST ANTIBIOTIC RESISTANCE AND GARANCE UPHAM, VICE-PRESIDENT, WORLD ALLIANCE AGAINST ANTIBIOTIC RESISTANCE GLOBAL AND NATIONAL GOVERNANCE • IPC AND SURVEILLANCE ONE HEALTH • NGO ENABLERS • RESEARCH & DEVELOPMENT ALTERNATIVES • INVESTMENT AND SOCIETY PUBLISHED IN OFFICIAL ASSOCIATION WITH THE WORLD ALLIANCE AGAINST ANTIBIOTIC RESISTANCE (WAAAR) AMR2018 TITLE page copy.pdf 1 13/08/2018 08:29 AMR CONTROL 2018 OVERCOMING GLOBAL ANTIMICROBIAL RESISTANCE Including contributions from: World Health Organization World Bank Federal Office of Public Health, Switzerland Spanish Agency of Medicines and Medical Devices (AEMPS) Centers for Disease Control and Prevention (CDC) Wellcome, UK Chatham House Iran University of Medical Sciences Befelatanana University Hospital, Madagascar China Global Health Research and Development, Shenzhen, China Apollo Cancer Institute, Chennai, India C University of Paris, France M University of Sydney, Australia Y CARB-X CM European Society for Clinical Microbiology and Infectious Diseases (ESCMID) MY International Union Against Tuberculosis and Lung Disease CY Ghent University Hospital, Belgium CMY Liverpool School of Tropical Medicine, UK London School of Hygiene & Tropical Medicine, UK K Emory University, USA Phages for Global Health University of Leicester, UK Lyon University, France Global Antibiotic Research and Development Partnership (GARDP) PUBLISHED IN OFFICIAL ASSOCIATION WITH THE WORLD ALLIANCE AGAINST ANTIBIOTIC RESISTANCE EDITORS-IN-CHIEF: DR JEAN CARLET, PRESIDENT, WORLD ALLIANCE AGAINST ANTIBIOTIC RESISTANCE AND GARANCE UPHAM, VICE-PRESIDENT, WORLD ALLIANCE AGAINST ANTIBIOTIC RESISTANCE • CANCER CONTROL PLANNING • RISK FACTORS • CANCER MANAGEMENT • DISEASE-SPECIFIC CANCERwww.amrcontrol.info CONTROL • PAEDIATRIC AND ADOLESCENT CANCER • PALLIATIVE CARE • REGIONAL INITIATIVES www.globalhealthdynamics.co.uk EDITORS-IN-CHIEF AMR CONTROL 2018 DR JEAN CARLET, PRESIDENT, WORLD ALLIANCE PUBLISHED BY GLOBAL HEALTH DYNAMICS AGAINST ANTIBIOTIC RESISTANCE (WAAAR) IN OFFICIAL ASSOCIATION WITH THE WORLD ALLIANCE GARANCE UPHAM, VICE-PRESIDENT, WORLD ALLIANCE AGAINST ANTIBIOTIC RESISTANCE AGAINST ANTIBIOTIC RESISTANCE (WAAAR) Contact details: [email protected] GLOBAL HEALTH DYNAMICS 20 QUAYSIDE, WOODBRIDGE, SUFFOLK For editorial enquires including submissions contact: IP12 1BH, UK [email protected] P: +44 1394 446023 www.globalhealthdynamics.co.uk E: [email protected] AMR CONTROL INTERNATIONAL ADVISORY SCIENTIFIC COMMITTEE: PUBLISHER J Professor Jacques Acar, (Special Expert, World Organisation TIM PROBART for Animal Health) Contact details: [email protected] J Dr Antoine Andremont, (Member, Advisory Group on Integrated Surveillance of AMR - WHO-AGISAR) For sponsorship and advertising contact: J Dr Awa Aidara-Kane, (Coordinator, WHO-AGISAR) [email protected] J Dr Jean Carlet, (President, ACdeBMR/WAAAR) or phone +44 (0) 1394 446023 J Dr Dame Sally Davies, (Chief Medical Officer, England) J Professor Ilona Kickbusch, (Director, Global Health Centre, DESIGN Graduate Institute, Geneva, Switzerland) MARRIOTT GRAPHICS J Dr Rashad Massoud, (Director, USAID’s Applying Science to www.smarriott.co.uk Strengthen and Improve Health Systems, ASSIST Project) J Mrs Precious Matsoso, (Director, Department of Health, COPY EDITOR South Africa) MADELINE PEARSON J Professor Cassandra L Quave, (Assistant Professor, Dermatology and Human Health, Emory University, USA) PRINTER J Dr Mario Raviglione, (Director, Global Tuberculosis PARK COMMUNICATIONS, UK global health Programme, WHO) dynamics All rights are reserved. No part of this publication may be reproduced, stored Professor John-Arne Røttingen, (Chief Executive, Research J in a retrieval system, or transmitted in any form or by any means, electronic, Council of Norway) mechanical, photocopying, recording or otherwise without the permission of the Publisher. J Dr Joseph Sitienei, (Head, National Strategic Programs, Ministry of Health, Kenya) The information contained in this publication is believed to be accurate at the time of manufacture. Whilst every care has been taken to ensure that the J Dr Steve Solomon, (Global Public Health Consulting and information is accurate, the Publisher and the World Alliance Against Antibiotic former AMR director, US Centers for Disease Control, USA) Resistance can accept no responsibility, legal or otherwise, for any errors or omissions or for changes to details given to the text or sponsored material. The J Dr Soumya Swaminathan, (Director General, Medical views expressed in this publication are not necessarily those of the Publisher or Research Council, India) of the World Alliance Against Antibiotic Resistance. J Professor Yonghong Xiao, (Vice-Director, State Key Application for reproduction should be made in writing to the Publisher. Laboratory for Diagnosis & Treatment of Inf. Diseases, Copyright © Global Health Dynamics 2018 China) ISBN 978-0-9576072-9-3 FIRST PUBLISHED 2018 J Professor Tong Zhang, (Civil Engineering Department, University of Hong-Kong, China) 2 AMR CONTROL 2018 CONTENTS CONTENTS 05 Introduction Dr Tedros Adhanom Ghebreyesus, Division of Healthcare Quality Promotion, Centers for Disease Director-General, World Health Organization Control and Prevention (CDC), USA, Dr Denise Cardo, Director, Division of Healthcare Quality Promotion (DHQP), National Center 06 Editorial Dr Jean Carlet, President, WAAAR and for Emerging and Zoonotic Infectious Diseases, (CDC), USA and Garance Upham, Vice-President, WAAAR Dr Michael Bell, Deputy Director, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious 08 Acknowledgements Diseases (CDC), USA 34 Containing cross-transmission of multi-resistant bacteria: A GLOBAL AND NATIONAL GOVERNANCE priority for controlling resistance in healthcare centres 10 AMR Control in discussion with… Dr Marc Sprenger, Director, Professor Vincent Jarlier, Bacteriology-Hygiene, University Paris 6; Antimicrobial Resistance Secretariat, World Health Organization Infection Control Officer, Direction for Medical Affairs, Assistance Publique – Hopitaux de Paris; Vice-President of WAAAR and 13 The Swiss recipe for containing antimicrobial resistance Dr Sandra Fournier, Central Infection Control Team, Assistance Mirko Saam, Co-Founder and Associate, Communication in Science Publique-Hopitaux de Paris, Paris, France Ltd, Geneva, Switzerland; Alexandre von Kessel, Senior Advisor, International Affairs Division, Federal Office of Public Health, Bern, 40 EU-JAMRAI: Europe fostering synergies to reduce the burden Switzerland and Karin Wäfler, StAR Project Leader, Federal Office of of AMR Belén Crespo, Director, Spanish Agency of Medicines and Public Health, Bern, Switzerland Medical Devices (AEMPS), Madrid, Spain; et al 18 Sponsored Feature 45 ESCMID: A scientific society with a vision and a mission on Antimicrobial Resistance (AMR): Stressing the role of the health antimicrobial resistance Professor Jesús Rodríguez-Baño, President, industry Martin Bernhardt, Head of Public Affairs Global Health, European Society of Clinical Microbiology and Infectious Diseases Sanofi (ESCMID), and Head, Infectious Diseases Division, Hospital Universitario Virgen Macarena, Spain 20 The antimicrobial resistance situation in Iran: The National Initiative and R&D to face AMR Abed Zahedi Bialvaei, PhD student, 47 Political opportunities and R&D to combat MDR-TB Department of Microbiology, Iran University of Medical Science, Dr José Luis Castro, Executive Director; Paul Jensen, Director of Tehran, Iran; Dr Hossein Samadi Kafil, Assistant Professor, Drug policy and strategy and Grania Brigden, Life Prize Project Lead, the Applied Research Center, Tabriz University of Medical Sciences, International Union Against Tuberculosis and Lung Disease (The Union) Tabriz, Iran; Dr Mohammad Ahangarzadeh Rezaee, Associate Professor, Infectious and Tropical Diseases Research Center, Tabriz 51 Addressing AMR in Madagascar: The experience of establishing University of Medical Sciences, Tabriz, Iran; Professor Mohammad a medical bacteriology laboratory at the Befelatanana University Rahbar, Professor Iranian Reference Health Laboratory, Member, Hospital in Antananarivo Dr Saïda Rasoanandrasana, Head of National Infection Control and Drug Surveillance System, Ministry of Microbiology, Befelatanana University Hospital Laboratory, Health and Medical Education, Iran and Dr Mohammad Asgharzadeh, Madagascar; Dr Lalaina Rahajamanana, Head, Bacteriology Professor of Molecular Biology, Drug Applied Research Center, Laboratory, Tsaralalàna Mother-Child University Hospital, Tabriz University Madagascar; Dr Camille Boussioux, Hospital Resident, Mérieux Foundation; Dr Marion Dudez, Medical Biologist, former Resident, 24 In order to protect antibiotics, which are a real treasure, we the Mérieux Foundation in Madagascar; Dr Odile Ouwe Missi should list them as UNESCO World Heritage! Dr Jean Carlet, Founder Oukem-Boyer, Mérieux Foundation Mali and Niger Country Manager, and President, WAAAR, Architect of the National Plan to Preserve Acting Director General, Charles Mérieux Center for Infectious Antibiotics, France and Garance Upham, Vice-President, WAAAR Disease in Mali; Luciana Rakotoarisoa, Mérieux Foundation Madagascar Country Manager; Dr Laurent Raskine, 26 AMR: A key focus of the upcoming 2019 Global Health Security Head, Specialized Biology, Mérieux
Load more

Recommended publications
  • Genomes of the T4-Related Bacteriophages As Windows on Microbial Genome Evolution
    Petrov et al. Virology Journal 2010, 7:292 http://www.virologyj.com/content/7/1/292 REVIEW Open Access Genomes of the T4-related bacteriophages as windows on microbial genome evolution Vasiliy M Petrov1, Swarnamala Ratnayaka1, James M Nolan2, Eric S Miller3, Jim D Karam1* Abstract The T4-related bacteriophages are a group of bacterial viruses that share morphological similarities and genetic homologies with the well-studied Escherichia coli phage T4, but that diverge from T4 and each other by a number of genetically determined characteristics including the bacterial hosts they infect, the sizes of their linear double- stranded (ds) DNA genomes and the predicted compositions of their proteomes. The genomes of about 40 of these phages have been sequenced and annotated over the last several years and are compared here in the con- text of the factors that have determined their diversity and the diversity of other microbial genomes in evolution. The genomes of the T4 relatives analyzed so far range in size between ~160,000 and ~250,000 base pairs (bp) and are mosaics of one another, consisting of clusters of homology between them that are interspersed with segments that vary considerably in genetic composition between the different phage lineages. Based on the known biologi- cal and biochemical properties of phage T4 and the proteins encoded by the T4 genome, the T4 relatives reviewed here are predicted to share a genetic core, or “Core Genome” that determines the structural design of their dsDNA chromosomes, their distinctive morphology and the process of their assembly into infectious agents (phage morphogenesis).
    [Show full text]
  • Dr. Martha Clokie Department of Infection, Immunity and Inflammation, University of Leicester, UK
    Graduate Schools Infection Immunity and Cancer, UniGe & UniL: CUS Biology & Medicine, CMU Seminars in Microbiology Monday, 8th December, 2014 Salle de séminaire 7172, CMU 11:00 – 12:00 Dr. Martha Clokie Department of Infection, Immunity and Inflammation, University of Leicester, UK The ecology, evolution and applications of Clostridium difficile bacteriophages Clostridia are Gram positive, anaerobic, sporulating bacteria of which some are important human pathogens. Clostridium difficile is present in the gut and is known to cause antibiotic treatment associated diarrhea. Bacteria have a core genome that is complemented by many genes that contribute to strain specific behavior and possibility to adapt to different environments. Some of these genes, which may encode virulence factors in pathogenic bacteria, are encoded by bacteriophages. The group of Martha Clokie has recently shown that a Clostridium phage encodes an agr-type quorum sensing system (QS), in which a secreted peptide represents the signaling molecule. It is suggested that the phage encoded agr system, which is missing the transcriptional activator AgrA, was taken from a bacterium and is transferred horizontally between Clostridia strains, thereby influencing the behavior of the lysogenic bacteria, though the interaction with resident agr quorum sensing systems in Clostridium. Hargreaves et al., Abundant and diverse clustered regularly interspaced short palindromic repeat spacers in Clostridium difficile strains and prophages target multiple phage types within this pathogen. MBio. 2014;5:e01045-13. Hargreaves et al., Bacteriophage behavioral ecology: How phages alter their bacterial host's habits. Bacteriophage. 2014 8;4:e29866. Hargreaves et al. What does the talking?: quorum sensing signalling genes discovered in a bacteriophage genome.
    [Show full text]
  • Translating Phage-Based Applications Into Clinically and Commercially
    SPEAKERS TO INCLUDE: Steffanie Strathdee Carl Merril Scott Stibitz & Tom Patterson CSO and Founder Microbiologist, Center for University of Adaptive Phage Biologics Evaluation and California San Diego Therapeutics Research FDA 29-30TH JANUARY 2019 | WASHINGTON D.C, USA Translating phage-based applications into clinically and commercially viable therapeutics Martha Clokie Biswajit Biswas Joe Campbell Professor of Chief, Division of Research Resources Microbiology Bacteriophage Science, Project Officer University of Biological Defense NIH (NIAID) Regulatory guidance to achieve clinical data from Cara Fiore, FDA Leicester Research Directorate US Naval Medical Research Center Strategies to access the market via the veterinary, personalized medicine and traditional pharmaceutical routes INSTITUTIONS PRESENT INCLUDE: Insights into investment drivers for phage therapy from NIH and Merck Facts on how to manufacture GMP phage Applications to overcome multi-drug resistance with combined approaches such as phage therapy and antibiotics www.phage-futures.com | +44 (0)20 3696 2920 | [email protected] WELCOME The Phage Futures Congress has the potential to act as a catalyst to further With antimicrobial resistance an ongoing worldwide issue, there is now a renewed interest cooperative and collaborative efforts in phage therapy as an alternative to antibiotics. There has been uncertainty as to whether to develop alternate Phage based approaches to phage therapy can be a commercially viable and FDA/EMA approved product. However, the the antibiotic
    [Show full text]
  • S41598-021-83773-1.Pdf
    www.nature.com/scientificreports OPEN Modelling the spatiotemporal complexity of interactions between pathogenic bacteria and a phage with a temperature‑dependent life cycle switch Halil I. Egilmez1, Andrew Yu. Morozov2,3* & Edouard E. Galyov2 We apply mathematical modelling to explore bacteria‑phage interaction mediated by condition‑ dependent lysogeny, where the type of the phage infection cycle (lytic or lysogenic) is determined by the ambient temperature. In a natural environment, daily and seasonal variations of the temperature cause a frequent switch between the two infection scenarios, making the bacteria‑phage interaction with condition‑dependent lysogeny highly complex. As a case study, we explore the natural control of the pathogenic bacteria Burkholderia pseudomallei by its dominant phage. B. pseudomallei is the causative agent of melioidosis, which is among the most fatal diseases in Southeast Asia and across the world. We assess the spatial aspect of B. pseudomallei‑phage interactions in soil, which has been so far overlooked in the literature, using the reaction‑difusion PDE‑based framework with external forcing through daily and seasonal parameter variation. Through extensive computer simulations for realistic biological parameters, we obtain results suggesting that phages may regulate B. pseudomallei numbers across seasons in endemic areas, and that the abundance of highly pathogenic phage‑free bacteria shows a clear annual cycle. The model predicts particularly dangerous soil layers characterised by high pathogen densities. Our fndings can potentially help refne melioidosis prevention and monitoring practices. Among major factors controlling bacterial numbers both in the wild and in artifcial environments are natural enemies known as bacteriophages or phages. Phages are viruses that can specifcally infect their host by attaching to particular bacterial receptors, injecting their genomic DNA (or RNA) into the host cell cytoplasm, and trigger- ing a process that can lead to phage replication or integration of phage genome into the host chromosome.
    [Show full text]
  • Ab Komplet 6.07.2018
    CONTENTS 1. Welcome addresses 2 2. Introduction 3 3. Acknowledgements 10 4. General information 11 5. Scientific program 16 6. Abstracts – oral presentations 27 7. Abstracts – poster sessions 99 8. Participants 419 1 EMBO Workshop Viruses of Microbes 2018 09 – 13 July 2018 | Wrocław, Poland 1. WELCOME ADDRESSES Welcome to the Viruses of Microbes 2018 EMBO Workshop! We are happy to welcome you to Wrocław for the 5th meeting of the Viruses of Microbes series. This series was launched in the year 2010 in Paris, and was continued in Brussels (2012), Zurich (2014), and Liverpool (2016). This year our meeting is co-organized by two partner institutions: the University of Wrocław and the Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences. The conference venue (University of Wrocław, Uniwersytecka 7-10, Building D) is located in the heart of Wrocław, within the old, historic part of the city. This creates an opportunity to experience the over 1000-year history of the city, combined with its current positive energy. The Viruses of Microbes community is constantly growing. More and more researchers are joining it, and they represent more and more countries worldwide. Our goal for this meeting was to create a true global platform for networking and exchanging ideas. We are most happy to welcome representatives of so many countries and continents. To accommodate the diversity and expertise of the scientists and practitioners gathered by VoM2018, the leading theme of this conference is “Biodiversity and Future Application”. With the help of your contribution, this theme was developed into a program covering a wide range of topics with the strongest practical aspect.
    [Show full text]
  • Biological and Genomic Characterization of a Novel Jumbo Bacteriophage, Vb Vham Pir03 with Broad Host Lytic Activity Against Vibrio Harveyi
    pathogens Article Biological and Genomic Characterization of a Novel Jumbo Bacteriophage, vB_VhaM_pir03 with Broad Host Lytic Activity against Vibrio harveyi Gerald N. Misol, Jr. 1,2 , Constantina Kokkari 1 and Pantelis Katharios 1,* 1 Institute of Marine Biology, Biotechnology and Aquaculture, Hellenic Center for Marine Research, 71500 Heraklion, Crete, Greece; [email protected] (G.N.M.J.); [email protected] (C.K.) 2 Department of Biology, University of Crete, 71003 Heraklion, Crete, Greece * Correspondence: [email protected] Received: 18 October 2020; Accepted: 14 December 2020; Published: 15 December 2020 Abstract: Vibrio harveyi is a Gram-negative marine bacterium that causes major disease outbreaks and economic losses in aquaculture. Phage therapy has been considered as a potential alternative to antibiotics however, candidate bacteriophages require comprehensive characterization for a safe and practical phage therapy. In this work, a lytic novel jumbo bacteriophage, vB_VhaM_pir03 belonging to the Myoviridae family was isolated and characterized against V. harveyi type strain DSM19623. It had broad host lytic activity against 31 antibiotic-resistant strains of V. harveyi, V. alginolyticus, V. campbellii and V. owensii. Adsorption time of vB_VhaM_pir03 was determined at 6 min while the latent-phase was at 40 min and burst-size at 75 pfu/mL. vB_VhaM_pir03 was able to lyse several host strains at multiplicity-of-infections (MOI) 0.1 to 10. The genome of vB_VhaM_pir03 consists of 286,284 base pairs with 334 predicted open reading frames (ORFs). No virulence, antibiotic resistance, integrase encoding genes and transducing potential were detected. Phylogenetic and phylogenomic analysis showed that vB_VhaM_pir03 is a novel bacteriophage displaying the highest similarity to another jumbo phage, vB_BONAISHI infecting Vibrio coralliilyticus.
    [Show full text]
  • Bacteriophage Therapy: an Alternative to Antibiotics? an Interview Professor Clokie
    Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie Published on December 2, 2015 at 6:39 AM Interview conducted by April Cashin-Garbutt, MA (Cantab) Professor Clokie THOUGHT LEADERS SERIES ...insight from the world’s leading experts What is a bacteriophage and how many different types of phage exist? A phage is a virus that infects a bacterium. People often get very confused about what the difference is between a virus and a bacterium. A virus, like a bacterium, is also a microorganism, but unlike bacteria, it needs to have a host to be able to replicate and propagate. All bacteria have these natural viruses, just like we have viruses that make us sick and our children sick. All bacteria have their own sets of viruses, so they’re very specific. A virus, for example, that infects E. coli bacteria wouldn’t infect a different species of bacteria. Over 90% of all viruses found that infect bacteria fall into three families or ‘types’ of viruses, but for the thousands P Saved from URL: http://www.news-medical.net/news/20151202/Bacteriophage-therapy-an-alternative-to-antibiotics-An-interview-P 1 rofessor-Clokie.aspx /10 Bacteriophage therapy: an alternative to antibiotics? An interview Professor Clokie of types of bacteria that exist, there are even more sub-types of viruses within these three families. The three major families of viruses are known as myoviruses, siphoviruses, podoviruses. They’re double-stranded DNA viruses and have different shapes. “Myo” means muscle and these viruses are have a long, contractile tail.
    [Show full text]
  • Bacteria Can Viral Infections As Well
    Paul Tyler, PSTT I BET YOU College Fellow, links DIDN’T KNOW... cutting-edge research with Bacteria get viral the principles of primary science infections as well [email protected] In 2016, a group of scientific experts from different fields Questions to ask children. came together to explore the most likely replacements What bacteria and viruses do you know? for antibiotics. They put together a list of 19 possible alternatives and narrowed it down to 10 that they felt What do bacteria and viruses do? were worth pursuing, and therefore funding. What is the difference between bacteria and virus? One of the possible alternatives considered is to use bacteriophages; viruses that attack and kill bacteria. This has been a common medical practice in some Eastern There are more than 30,000 species of bacteria defined European countries for nearly 100 years but research on Earth and they are found just about everywhere into bacteriophages in Western countries stopped when from the freezing Antarctic to the hottest volcanic antibiotics were discovered. environments. They are simple single celled organisms that reproduce by copying their DNA and then splitting One of the world’s leading experts on bacteriophages into two identical offspring cells (Figure 1). is Professor Martha Clokie, a microbiologist at the University of Leicester. Her research team are working Figure 1. Bacteria are types of single-celled organism. to understand the complex interactions between bacteria and bacteriophages in different environments. There is increasing evidence that viruses can control their bacterial hosts in a variety of ways, even in the human body.
    [Show full text]
  • Martha Clokie
    microbiologytoday vol35|aug08 quarterly magazine of the society for general microbiology life’s a gas microbes and oxygen … and it’s hydrogen methane: a natural gas microbial genetics of seaside smells toxic gases of the nitrogen cycle contents vol35(3) regular features 106 News 138 Schoolzone 146 Hot off the Press 114 Microshorts 142 Gradline 150 Going Public 136 Meetings 145 Addresses 154 Reviews other items 141 Obituary – Professor Norbert Pfennig articles 116 Microbes and oxygen 128 On the microbial genetics Martha Clokie of seaside smells A range of micro-organisms and even, Andy Johnston surprisingly, viruses are involved in oxygen DMS, responsible for the familiar aroma of the shore, is production on planet Earth. produced by complex microbial processes. 132 NO laughing matter: 120 Life’s a gas... and it’s the toxic gases of the hydrogen nitrogen cycle Mark D. Redwood & David J. Richardson, Lynne E. Macaskie Andrew J. Thomson & Some microbes gain energy by releasing hydrogen into the environment, a process which has many exciting Nicholas J. Watmough applications. Nitric oxide is an important part of the nitrogen cycle, but in some circumstances it can be a greenhouse gas. 124 Methane: a natural gas 156 Comment: Bad reporting in the media is hard to swallow James Chong Methane may be a greenhouse gas, but John Heritage conversely it also has great potential as a source Sometimes it can be a good thing that today’s newspaper is of green energy. tomorrow’s chip wrappings. Cover image A natural-gas fireball. Photos.com / Jupiter Images The views expressed Editor Dr Matt Hutchings––Editorial Board Dr Sue Assinder, Dr Paul Hoskisson, Professor Bert Rima––Managing Editor Janet Hurst––Assistant Editors Lucy Goodchild & Faye Stokes by contributors are not Editorial Assistant Yvonne Taylor––Design & Production Ian Atherton––Contributions are always welcome and should be addressed to the Editor c/o SGM HQ, Marlborough House, necessarily those of the Basingstoke Road, Spencers Wood, Reading RG7 1AG–Tel.
    [Show full text]
  • Biological Sciences
    Module Specification BS1030 Biochemistry Academic Year: 2017/8 Student Workload (hours) Module Level: Year 1 Lectures 50 Scheme: UG Seminars Department: Biological Sciences Practical Classes & Workshops 30 Credits: 30 Tutorials 6 Fieldwork Project Supervision Guided Independent Study 214 Demonstration Supervised time in studio/workshop Work Based Learning Placement Year Abroad Total Module Hours 300 Period: Semester 1 Occurence: E Coordinator: Mark Leyland Mark Scheme: UG Pass for Credit No. Assessment Description Weight % Qual Mark Exam Hours Ass't Group Alt Reass't 001 Practical report 15 002 Report 15 003 Online assessment 10 004 Examination (Final) 60 2 Intended Learning Outcomes By the end of this module students should be able to: Explain the basic chemical principles that underpin biochemistry Describe the structures of biological macromolecules and their components Discuss the principles and mechanisms of information transfer from DNA to proteins Explain the basic principles of enzyme catalysis Describe the relationship between structure and function for some proteins Outline the key features of biological membranes Describe the key metabolic processes within a cell and recognize the importance of regulation Combine facts and ideas in clear and concise written and oral communications Demonstrate basic biochemical laboratory skills using safe laboratory practice Analyse experimental results using core data-handling skills Teaching and Learning Methods Lectures, practicals, work sessions and tutorials. Assessment Methods Laboratory
    [Show full text]
  • Phages in Anaerobic Systems
    viruses Review Phages in Anaerobic Systems Santiago Hernández 1 and Martha J. Vives 1,2,* 1 Department of Biological Sciences, Universidad de los Andes, Bogotá 111711, Colombia; [email protected] 2 School of Sciences, Universidad de los Andes, Bogotá 111711, Colombia * Correspondence: [email protected] Received: 1 August 2020; Accepted: 8 September 2020; Published: 26 September 2020 Abstract: Since the discovery of phages in 1915, these viruses have been studied mostly in aerobic systems, or without considering the availability of oxygen as a variable that may affect the interaction between the virus and its host. However, with such great abundance of anaerobic environments on the planet, the effect that a lack of oxygen can have on the phage-bacteria relationship is an important consideration. There are few studies on obligate anaerobes that investigate the role of anoxia in causing infection. In the case of facultative anaerobes, it is a well-known fact that their shifting from an aerobic environment to an anaerobic one involves metabolic changes in the bacteria. As the phage infection process depends on the metabolic state of the host bacteria, these changes are also expected to affect the phage infection cycle. This review summarizes the available information on phages active on facultative and obligate anaerobes and discusses how anaerobiosis can be an important parameter in phage infection, especially among facultative anaerobes. Keywords: anaerobic; aerobic; facultative; bacteriophage; bacteria 1. Introduction Phages, the most abundant biological organisms on Earth, regulate bacterial populations by means of their lytic activity. Bacteria actively participate in biogeochemical cycles [1], especially in the carbon and nitrogen cycles [2–4]; also, they produce a great percentage of the atmospheric oxygen (cyanobacteria), and recycle the oxygen in the soil [5].
    [Show full text]
  • UC Irvine Electronic Theses and Dissertations
    UC Irvine UC Irvine Electronic Theses and Dissertations Title Evolution of bacteriophages infecting Enterococcus from the human microbiome Permalink https://escholarship.org/uc/item/3dk3316p Author Wandro, Stephen Joseph Publication Date 2019 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA, IRVINE Evolution of bacteriophages infecting Enterococcus from the human microbiome DISSERTATION submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Molecular Biology and Biochemistry by Stephen Joseph Wandro Dissertation Committee: Assistant Professor Katrine Whiteson, Chair Professor Jennifer Martiny Associate Professor Ilhem Messaoudi 2019 Chapter 1 © 2018 American Society for Microbiology Chapter 2 © 2017 American Society for Microbiology Chapter 3 © 2018 Frontiers Media All other materials © 2019 Stephen Wandro and Katrine Whiteson DEDICATION To my parents, Bob and Cathy Thank you for your love and support And to my partner, Linh Anh Let’s write the next chapter together ii TABLE OF CONTENTS Page LIST OF FIGURES iv LIST OF TABLES vi ACKNOWLEDGMENTS vii CURRICULUM VITAE viii ABSTRACT OF THE DISSERTATION x INTRODUCTION 1 CHAPTER 1: The Microbiome and Metabolome of Preterm 9 Infant Stool Are Personalized and Not Driven by Health Outcomes, Including Necrotizing Enterocolitis and Late-Onset Sepsis CHAPTER 2: Making It Last: Storage Time and Temperature Have
    [Show full text]